Department of Clinical Microbiology
Extra Seminar
Title:
High-Throughput Screening in an Academic Setting\,
a Bona Fide Path to Novel Therapeutics and Tool Molecules?
Speaker:
Kurt Lackovic
Walter and Eli
za Hall Institute Melbourne\, Australia
Place: Betula\, Univ
ersity Hospital\, building 6 M
The Walter and E
liza Hall Institute of Medical Research was one of the first academic inst
itutions in the world to establish a high-throughput screening facility. H
ow this Facility operates\, along with the format of projects\, outcomes t
o date\, examples of projects\, and recent expansion to include high-conte
nt screening will be discussed.
\n
Biography Paragraph:
\nDr Kurt Lackovic completed his PhD in analytical chemistry in 2003. H e then relocated to Sweden for his initial post doctoral placement\, at th e Department of Medical Biosciences\, Umeå University\, Sweden. Dr Lackovi c returned to Melbourne in October 2006\, immediately taking a position in the WEHI High-Throughput Chemical Screening (HTCS) Facility. In his curre nt role\, Dr Lackovic is responsible for managing collaborative research p rojects seeking lead-like molecules across a broad range of target classes and disease types\, developing novel techniques\, and reporting findings. In addition\, he is responsible for the HTCS Facility's high-content imag ing capabilities.
\n
Recent publications include:
Croker et al. Fas-mediated neutrophil apoptosis is accelerated
by Bid\, Bak\, and Bax and inhibited by Bcl-2 and Mcl-1. Proc Natl AcadSci
U S A. 2011 108:13135-40.
Lackovic K\, Parisot JP\, Sleebs N\, Bae
ll JB\, Debien L\, Watson KG\, Curtis JM\,Handman E\, Street IP\, Kedziers
ki L. Inhibitors of Leishmania GDP-mannose pyrophosphorylase identified by
high-throughput screening of small-molecule chemical library. Antimicrob
Agents Chemother. 2010 54:1712-9.
Department of Clinical Microbiology
E
xtra Seminar
Title:
High-Throughput Screening in an Ac
ademic Setting\, a Bona Fide Path to Novel Therapeutics and Tool Molecules
?
Speaker:
Kurt Lackovic
Walter and Eliza Hall Institute Melbourne\, Australia
Pla
ce: Betula\, University Hospital\, building 6 M
The Walter and Eliza Hall Institute of Medical Research was one of the fi
rst academic institutions in the world to establish a high-throughput scre
ening facility. How this Facility operates\, along with the format of proj
ects\, outcomes to date\, examples of projects\, and recent expansion to i
nclude high-content screening will be discussed.
\n
Biograp hy Paragraph:
\nDr Kurt Lackovic completed his PhD in analytical che mistry in 2003. He then relocated to Sweden for his initial post doctoral placement\, at the Department of Medical Biosciences\, Umeå University\, S weden. Dr Lackovic returned to Melbourne in October 2006\, immediately tak ing a position in the WEHI High-Throughput Chemical Screening (HTCS) Facil ity. In his current role\, Dr Lackovic is responsible for managing collabo rative research projects seeking lead-like molecules across a broad range of target classes and disease types\, developing novel techniques\, and re porting findings. In addition\, he is responsible for the HTCS Facility's high-content imaging capabilities.
\n
Recent publicatio
ns include:
Croker et al. Fas-mediated neutrophil apoptosi
s is accelerated by Bid\, Bak\, and Bax and inhibited by Bcl-2 and Mcl-1.
Proc Natl AcadSci U S A. 2011 108:13135-40.
Lackovic K\, Parisot JP
\, Sleebs N\, Baell JB\, Debien L\, Watson KG\, Curtis JM\,Handman E\, Str
eet IP\, Kedzierski L. Inhibitors of Leishmania GDP-mannose pyrophosphoryl
ase identified by high-throughput screening of small-molecule chemical lib
rary. Antimicrob Agents Chemother. 2010 54:1712-9.